EGFR and non-small cell lung carcinoma: Notably, EGFR represents a paradigm of targetable oncogenic drivers, with a constant increase in terms of translational knowledge and clinical applications; moreover, the subsequent concept of acquired resistance mechanisms, which in turn might become therapeutic targets, is leading the management of EGFR-mutated NSCLC beyond its initial limits [1].